Related Experiment Video
Updated: Jan 31, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified
Li Li1, Li Wei1, Zi-Gang Xu1
1Department of Dermatology, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, No. 56 Nanlishi Road, Beijing, 100045, China.
Insights
Propranolol treatment for infantile hemangioma (IH) in preterm infants showed no increased risks of adverse effects or growth impairment compared to term infants up to age three years.
Area of Science:
- Pediatric pharmacology
- Neonatology
- Dermatology
Background:
- Infantile hemangioma (IH) treatment with propranolol raises concerns for preterm infants.
- Preterm infants' immature development may increase risks of adverse effects and growth impairment.
Purpose of the Study:
- To compare the incidence of long-term adverse effects and growth impairment in preterm versus term infants treated for IH with propranolol.
- To assess the safety and efficacy of propranolol in preterm infants with IH.
Main Methods:
- Retrospective analysis of clinical data from 55 preterm and 180 term infants with IH.
- All infants received oral propranolol for 6 months.
- Comparison of adverse effect incidence and growth parameters (height, weight, head circumference) up to age 3 years.
Main Results:
- No significant differences in general characteristics or adverse effect incidence between preterm and term infants.
- Preterm infants' growth (height, weight, head circumference) up to age 3 years did not differ from normal references.
- Term infants showed significantly higher weight and head circumference at 1 year compared to normal references.
Conclusions:
- Six-month propranolol treatment for IH did not elevate risks for adverse effects or growth impairment in preterm infants compared to term infants.
- Propranolol appears to be a safe treatment option for infantile hemangioma in preterm infants up to age three years.
Background:
Concerns have been raised that propranolol treatment of infantile hemangioma (IH) may be associated with increased risks of adverse effects and growth impairment in preterm infants due to their immature development.
Objective:
This study aimed to find out whether treatment of IH with propranolol in preterm infants is associated with higher incidences of long-term adverse effects and growth impairment in comparison with term infants.
Methods:
The clinical data of 55 preterm infants and 180 term infants with IH treated with oral propranolol for 6 months were retrospectively collected and analyzed.
Results:
The preterm and term patients did not differ significantly in terms of the general characteristics and adverse effect incidence (all p > 0.05). Height, weight, and head circumference of the preterm infants at ages 1, 2, and 3 years did not differ significantly from the normal references (all p > 0.05). In the term patients, only 1-year-old female weight and head circumference were significantly higher than the normal references (both p < 0.05).
Conclusion:
Treatment of IH with propranolol for 6 months did not increase the risks for adverse effects or growth impairment up to age 3 years in preterm versus term patients in our study.
Related Concept Videos
Increasing Function
Relative Risk
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Increased Body Temperature
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

